ECULIZUMAB
eculizumab 300 mg/30 mL injection, 30 mL vial
ECULIZUMAB (10194M)
10194M
Manner of administration:Injection
Restriction
Indication: Atypical haemolytic uraemic syndrome (aHUS)
Treatment phase: Continuing treatment
Restriction
Indication: Atypical haemolytic uraemic syndrome (aHUS)
Treatment phase: Extended Continuing treatment
Restriction
Indication: Atypical haemolytic uraemic syndrome (aHUS)
Treatment phase: Recommencement of treatment
Restriction
Indication: Atypical haemolytic uraemic syndrome (aHUS)
Treatment phase: Continuing recommencement of treatment
Restriction
Indication: Atypical haemolytic uraemic syndrome (aHUS)
Treatment phase: Switch from PBS-subsidised ravulizumab (all phases) - loading dose
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 5 | DPMQ: $5,407.48 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Soliris | |||||